Rituximab Efficacy in Pediatric Nephrotic Syndrome: 42-Patient Retrospective Cohort

Supplementary file 1 from a retrospective cohort study by Yue Xi, last updated April 2026. It contains clinical outcome data for 42 pediatric patients with steroid-dependent or frequently relapsing nephrotic syndrome, assessing rituximab efficacy across histological subtypes MCD and FSGS over a 6-year follow-up.

Use Cases

• Compare relapse-free survival rates between MCD and FSGS patient groups based on the reported 96-month outcomes.
• Analyze the relationship between rituximab infusion count (median 4) and relapse frequency reduction mentioned in the results.
• Model clinical remission rates (90.5% complete remission) following rituximab treatment in a pediatric cohort.
• Investigate potential demographic factors (median age 5.1 years, 67% male) in treatment response for SDNS/FRNS.

Strengths

• Includes biopsy-proven histological subtype data for all 42 patients (85.7% MCD, 14.3% FSGS).
• Reports specific clinical metrics: median age at diagnosis (5.1 years), median infusion count (4), and complete remission rate (90.5%).
• Contains longitudinal outcome data with a 6-year follow-up period and relapse-free survival analysis.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The study notes a small sample size for the FSGS subgroup (6 patients), limiting generalizability of comparative findings.

Provenance

Source

Yue Xi via figshare

Collection Method

Retrospective cohort study of clinical records.

Time Range

Covers a 6-year patient follow-up period (specific years not stated).

Freshness

Last updated 2026-04 23 04:16:30; freshness should be verified.

Geography

Geographic coverage of patient cohort is not specified.